Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America Read the full story

Bristol-Myers Squibb and ZAI Lab have signed a definitive agreement Read the full story

Bavarian Nordic and Bristol-Myers Squibb announced an exclusive option to license and commercialize PROSTVAC Read the full story

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies Read the full story

Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus Read the full story

Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib Read the full story

Seattle Genetics and Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials Read the full story

Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) announced have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies Read the full story

Ono Pharmaceutical, Bristol-Myers Squibb Company and Kyowa Hakko Kirin have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study Read the full story